Next Article in Journal
Identification and RNAi Profile of a Novel Iflavirus Infecting Senegalese Aedes vexans arabiensis Mosquitoes
Next Article in Special Issue
Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
Previous Article in Journal
Population Structure of Lassa Mammarenavirus in West Africa
Previous Article in Special Issue
Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners
Open AccessReview

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis

Department of Molecular and Clinical Medicine, University of Dundee, Medical School, Ninewells Hospital, Jacquie Woods Centre, Ninewells Drive, Dundee DD1 9SY, UK
*
Authors to whom correspondence should be addressed.
Viruses 2020, 12(4), 438; https://doi.org/10.3390/v12040438
Received: 6 March 2020 / Revised: 31 March 2020 / Accepted: 9 April 2020 / Published: 13 April 2020
(This article belongs to the Special Issue Virus-Like Particle Vaccines)
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic disease has yet been licensed. The present review summarises recent scientific advances, identifying interleukin-13 as an excellent candidate to validate the concept of anti-cytokine vaccination. Based on numerous clinical studies, long-term elimination of IL-13 is not expected to trigger target-related serious adverse effects and is likely to be safer than combined targeting of IL-4/IL-13. Furthermore, recently published results from large-scale trials confirm that elimination of IL-13 is highly effective in atopic dermatitis, an exceedingly common condition, as well as eosinophilic esophagitis. The distinctly different mode of action of a polyclonal vaccine response is discussed in detail, suggesting that anti-IL-13 vaccination has the potential of outperforming monoclonal antibody-based approaches. Finally, recent data have identified a subset of follicular T helper cells dependent on IL-13 which selectively trigger massive IgE accumulation in response to anaphylactoid allergens. Thus, prophylactic IL-13 vaccination may have broad application in a number of allergic conditions. View Full-Text
Keywords: VLP; IL-13; interleukin-13; vaccine; Tfh cells VLP; IL-13; interleukin-13; vaccine; Tfh cells
Show Figures

Figure 1

MDPI and ACS Style

Foerster, J.; Molęda, A. Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis. Viruses 2020, 12, 438.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop